Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma

J Dermatol. 2019 Jan;46(1):e43-e44. doi: 10.1111/1346-8138.14492. Epub 2018 Jun 4.

Authors

Maria Cho¹, Yumi Nonomura¹, Yo Kaku¹, Shuichiro Nakabo², Yuichiro Endo¹, Atsushi Otsuka¹, Kenji Kabashima¹

Affiliations

¹ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

PMID: 29863795
DOI: 10.1111/1346-8138.14492

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
Biopsy
Fingers
Humans
Male
Melanoma / drug therapy*
Nivolumab / adverse effects*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Scleroderma, Localized / diagnosis
Scleroderma, Localized / immunology*
Scleroderma, Localized / pathology
Skin / immunology
Skin / pathology
Skin Neoplasms / drug therapy*
Syndrome

Substances

Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab